This transcript has been edited for clarity.
Hello. I'm Ileana Piña from Thomas Jefferson University in Philadelphia, and this is my blog.
I want to talk to our audience today about a study that was published relatively recently, mostly out of Europe, named STRONG-HF. This is the baby of Alexander Mebazaa, a wonderful heart failure cardiologist from Paris, and Gad Cotter in Israel.
Get The Drugs on Board Quickly
They thought that we need to get the heart failure drugs on board. You've heard me say so many times on these recordings that we need to get the patients on the right drugs. We've talked about the four pillars of care for low ejection fraction, the heart failure with reduced ejection fraction (HFrEF) population. This includes a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which is our newest addition; a renin-angiotensin system (RAS) inhibitor (in patients with NYHA class II-III disease, the guidelines prefer the angiotensin receptor-neprilysin inhibitor [ARNI]); a beta-blocker; and a mineralocorticoid receptor antagonist (MRA), which is either spironolactone or eplerenone.
How do we do this? We've often talked about how it may take 3 months to do this. Well, the STRONG-HF concept — and it was a randomized trial vs usual care — is to get the drugs on relatively quickly and at good doses.
Cardiologists, Patients Can Talk Drug Costs
Early or Delayed AF Ablation After Heart Failure Hospitalization?
Skill Checkup: A 69-Year-Old Woman With Worsening Heart Failure and Iron Deficiency
COMMENTARY
STRONG-HF: This Is the Science, Let's Get It Done
Ileana L. Piña, MD, MPH
DisclosuresApril 03, 2023
This transcript has been edited for clarity.
Hello. I'm Ileana Piña from Thomas Jefferson University in Philadelphia, and this is my blog.
I want to talk to our audience today about a study that was published relatively recently, mostly out of Europe, named STRONG-HF. This is the baby of Alexander Mebazaa, a wonderful heart failure cardiologist from Paris, and Gad Cotter in Israel.
Get The Drugs on Board Quickly
They thought that we need to get the heart failure drugs on board. You've heard me say so many times on these recordings that we need to get the patients on the right drugs. We've talked about the four pillars of care for low ejection fraction, the heart failure with reduced ejection fraction (HFrEF) population. This includes a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which is our newest addition; a renin-angiotensin system (RAS) inhibitor (in patients with NYHA class II-III disease, the guidelines prefer the angiotensin receptor-neprilysin inhibitor [ARNI]); a beta-blocker; and a mineralocorticoid receptor antagonist (MRA), which is either spironolactone or eplerenone.
How do we do this? We've often talked about how it may take 3 months to do this. Well, the STRONG-HF concept — and it was a randomized trial vs usual care — is to get the drugs on relatively quickly and at good doses.
© 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: STRONG-HF: This Is the Science, Let's Get It Done - Medscape - Apr 03, 2023.
Tables
Authors and Disclosures
Authors and Disclosures
Author
Ileana L. Piña, MD, MPH
Professor of Medicine/Cardiology/Heart Failure/Transplant; Quality Officer, Cardiovascular Line, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; Clinical Professor of Medicine, Central Michigan University College of Medicine, Mount Pleasant, Michigan; Adjunct Professor of Epidemiology and Biostatistics, Population & Quantitative Health Sciences, Case Western University, Cleveland, Ohio
Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, office, partner, employee, advisor, consultant, or trustee for: US Food and Drug Administration; Center for Devices and Radiological Health